Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

VivoSim Labs Q2 2026 Results: Net Loss of $475K, Loss Narrows

VivoSim Labs reported a net loss of $1.8 million for the six months ended September 30, 2026, a significant improvement from the $5.4 million loss in the prior year period, primarily due to a $5.0 million milestone payment gain. The company transitioned its business model toward 3D human tissue model testing services following FDA regulatory shifts, while significantly increasing its outstanding share count from 2.9 million to 18.1 million during the period.

Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Revenue0.10.0
Net income-0.5-2.5
EPS (diluted, $ a share)$-0.03$-0.98

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+82.1%
Source

10-Q filed with the SEC, NASDAQ: VIVS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

VivoSim Labs, INC.: key numbers

Share price
$0.1237Close, Nov 16
Market cap
$2.51M
Shares outstanding
20.28MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from VivoSim Labs, INC.

All →
4:05 PM ET 8-K
Business Update

VivoSim Labs Business Update

VivoSim Labs' subsidiary Organovo entered into a second lease amendment for its principal executive offices in San Diego. The amendment reduces the leased square footage by vacating Suite 202, extends the term for Suite 100 through April 2028, and sets a new monthly base rent of $43,072.85 with a partial rent abatement in early 2027.

Counterparty
San Diego Inspire 2, LLC
Term
through April 30, 2028
4:06 PM ET 8-K
Shareholder Meeting

VivoSim Labs Shareholder Meeting

VivoSim Labs held its 2026 Annual Meeting of Stockholders where shareholders elected two Class III directors and ratified the appointment of Rosenberg Rich Baker Berman P.A. as auditors. Stockholders also approved an amendment to the 2022 Equity Incentive Plan to increase the share reserve by 3,165,000 shares and passed an advisory vote on executive compensation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.